Navigation Links
Two cardiovascular proteins pose a double whammy in Alzheimer's

Researchers have found that two proteins which work in tandem in the brain's blood vessels present a double whammy in Alzheimer's disease. Not only do the proteins lessen blood flow in the brain, but they also reduce the rate at which the brain is able to remove amyloid beta, the protein that builds up in toxic quantities in the brains of patients with the disease.

The work, described in a paper published online Dec. 21 in the journal Nature Cell Biology, provides hard evidence directly linking two processes thought to be at play in Alzheimer's disease: reduction in blood flow and the buildup of toxic amyloid beta. The research makes the interaction between the two proteins a seductive target for researchers seeking to address both issues.

Scientists were surprised at the finding, which puts two proteins known for their role in the cardiovascular system front and center in the development of Alzheimer's disease.

"This is quite unexpected," said Berislav Zlokovic, M.D., Ph.D., a neuroscientist and a senior author of the study. "On the other hand, both of these processes are mediated by the smooth muscle cells along blood vessel walls, and we know that those are seriously compromised in patients with Alzheimer's disease, so perhaps we shouldn't be completely surprised."

The new findings are the result of a seven-year collaboration between two laboratories. Zlokovic heads the Center for Neurodegenerative and Vascular Brain Disorders, looking at molecular roots of diseases like Alzheimer's. Several years ago, after he found that several genes well known to cardiovascular researchers seemed to be especially affected in Alzheimer's patients, he turned to Joseph Miano, Ph.D. to help analyze the findings. Miano is interim director of Aab Cardiovascular Research Institute and associate professor of Medicine, and he is senior co-author of the new study.

"To some, it might seem odd that a cardiovascular group would intersect with a neuroscience group to study Alzheimer's disease," Miano said. "But there's a great deal of evidence to suggest that Alzheimer's disease is a problem having much to do with the vascular plumbing. And Rochester is the type of institution where partnerships like these are easy to strike up."

For 15 years Zlokovic's laboratory has focused on the molecular mechanisms regulating blood supply and the role of the blood-brain barrier in the development of Alzheimer's disease. It's not simply that reduced blood supply hurts brain cells by causing a shortage of oxygen and other nutrients. Rather, deterioration of blood flow seems to gum up the brain's ability to remove toxic amyloid beta.

Normally, amyloid is picked up efficiently by blood vessels that then whisk the toxic trash away. But in Alzheimer's disease, the system no longer is able to keep up with the body's production of the substance. The molecular trash accumulates, and Zlokovic and others believe the buildup kills brain cells.

The current work focuses on two proteins well known to cardiovascular researchers, SRF (serum response factor) and myocardin. The two work together within smooth muscle cells that line blood vessels to activate genes that are necessary for smooth muscle to function properly. SRF binds to certain snippets of DNA called CArG boxes and serves as an anchor, while myocardin piggybacks along and turns on the genes to which SRF sticks. Together they act as a master switch that determines whether smooth muscle cells contract one of many ways the body controls just how much blood is flowing in the body.

Two years ago, Zlokovic and Miano published a study showing that the two proteins are much more active in the blood vessels of brains of people with Alzheimer's disease than in people who do not have the disease. They showed that when they reduced the activity of the proteins, blood flow in the brain increased, and when the genes were more active, blood flow decreased.

The latest report goes further, implicating the molecular duo in the slowed removal of amyloid beta. The team found that SRF and myocardin working together turn on a molecule known as SREBP2. That protein inhibits a molecule known as LRP-1, which helps the body remove amyloid beta. In other words, when SRF and myocardin are active, toxic amyloid beta accumulates.

The findings came primarily from the team's studies of brain cells taken from people who had Alzheimer's disease and comparing them to cells from healthy elderly people.

Compared to the smooth muscle cells from healthy adults, the cells from patients with Alzheimer's disease had about five times as much myocardin and four times as much SRF, about five times as much SREBP2, and about 60 percent less LRP-1. That translated into a reduced ability to remove amyloid beta: Cells taken from patients with the disease had only about 30 percent of the ability to remove the substance as cells taken from their healthy counterparts.

When the team lowered levels of SRF to the same level that exists in healthy cells, the cells from Alzheimer's patients improved in their ability to remove amyloid beta, doing it just as well as cells from healthy individuals. Conversely, when the team boosted levels of SRF and myocardin in the healthy cells, the changes lowered by about 65 percent those cells' ability to remove amyloid beta.

In mice, the team found parallel results. When the team boosted SRF or myocardin in healthy mice, those mice had about twice as much SREBP2 in their smooth muscle cells in the brain's blood vessels. They also had 90 percent less LRP-1, three times as much amyloid beta in their arteries, and 70 percent more amyloid beta in their brain tissue.

When the team reduced SRF and myocardin in mice prone to developing Alzheimer's disease, those mice had 60 percent less SREBP2, about four times as much LRP-1, and a 50-percent reduction in amyloid beta in their blood vessels.

The first author of the study is Robert Bell, a graduate student in Zlokovic's laboratory who is in Department of Pathology and Laboratory Medicine's graduate program. He had searched for months, without success, for evidence of a direct effect on LRP-1 by SRF/myocardin. A subsequent literature search turned up findings that the molecules might affect SREBP2. With that finding, the team was able to move forward and put the whole picture together.

Now the team has turned its attention to studying the role of hypoxia, which seems to play a role in turning on myocardin, as well as searching for molecules that block the hookup between SRF and myocardin.


Contact: Tom Rickey
University of Rochester Medical Center

Related medicine news :

1. The Endovascular Forum, Inc. and the Society for Cardiovascular Angiography and Interventions Partner to Extend the Influence of Electronic Medical Care Innovation to Cardiovascular Medicine Through www.EndoVascular.Org, a Global, Multi-disciplinary Care
2. Terumo Corporation Announces Settlement of all Patent Litigation with Maquet Cardiovascular
3. Foundation Radiology Group Adds World Class Cardiovascular Imaging Expert, Dr. Sanj Katyal, to Staff
4. Presence of gum disease may help dentists and physicians identify risk for cardiovascular disease
5. Hospitals to Lose an Average $10,000 to $20,000 per Case on Common Cardiovascular Procedures Under Medicares Value-based Purchasing Program
6. New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug
7. Correspondent Honored for Reporting on Cardiovascular Disease
8. The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease
9. Vitamins E and C supplements not effective for prevention of cardiovascular disease in men
10. Researchers discover new risk factor for cardiovascular disease, and a way to control it
11. Webcast Alert: Isis Pharmaceuticals Cardiovascular Program Review
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... IBM software products, introduced a new company, RightSensor™ LLC, an Internet of Things ... capability. RightSensor™ provides a fully-managed approach for customers requiring sensor hardware for ...
(Date:10/13/2015)... CHENNAI, India (PRWEB) , ... October 13, 2015 , ... ... advanced camera solutions, today announced See3CAM_CU40, the industry’s first RGB-IR pixel format ... module. See3CAM_CU40, a new member of e-con’s See3CAM family of UVC USB 3.0 cameras, ...
(Date:10/13/2015)... ... October 13, 2015 , ... Protein is essential to good health. You need ... blood. But how much protein does the average man need in order to stay ... the October 2015 issue of Harvard Men's Health Watch . Most Americans get ...
(Date:10/13/2015)... ... 2015 , ... T-System and Centegra Health System, a prominent ... visits per year, today announced the successful and rapid deployment of EV™, an ... financial outcomes. , In less than four days, Centegra Hospitals McHenry ...
(Date:10/13/2015)... ... October 13, 2015 , ... World Patent Marketing , a ... snow melting invention that helps people in clearing snow away from the streets and ... grow at 3.8% per year," says Scott Cooper, CEO and Creative Director of World ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 13, 2015  Measurement in accountable care programs ... financial incentives, but gaps in measurement can result ... health systems. A new, peer-reviewed study published ... explores measurement gaps for high-priority conditions ... --> --> "These ...
(Date:10/13/2015)... , Oct. 13, 2015  Nanomedical Diagnostics, ... use in research and diagnostics, announces the completion ... million led by Serra Ventures. ... is providing low-cost, easy-to-use monitoring and diagnostic platforms ... decisions. The funding round will enable the company ...
(Date:10/13/2015)... 13 2015 ... the "US & European Markets for ... report to their offering. --> ... of the "US & European Markets ... (2010-2021)" report to their offering. ...
Breaking Medicine Technology: